ClinicalTrials.gg
RecruitingNCT07356154Updated Oct 20, 2026

A Study of Revumenib and Mezigdomide in People With Leukemia

A Phase 1/2 interventional study of Revumenib and Mezigdomide in Leukemia, Acute Leukemia and Relapse Leukemia, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 10 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Oct 20, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
52
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 87 studies in Leukemia by Memorial Sloan Kettering Cancer Center — 4 open to participants now, 12 under way, none of them phase 3. Leukemia · Memorial Sloan Kettering Cancer Center.

Planned enrollment
20th of 61
52 · median 38
Started
2026
with 1 other
Phase 1/2
9 of 87
1 open now
Primary completion
2029-01
later than 10 of 11 live
Registered
86th of 87
by date

Among the 87 studies in Leukemia by Memorial Sloan Kettering Cancer Center, this one is the 20th largest by planned enrollment of the 61 interventional ones that give a count, is one of 2 that started in 2026, is one of 9 in phase 1/2, reaches primary completion later than 10 of the 11 other live ones, and was the 86th registered.

Leukemia

2,382 studies on the registry are indexed under Leukemia; 252 are open to participants now.

Browse Leukemia studies →

Open to participants now

4 of the 87 studies in Leukemia by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 206 Leukemia studies recruiting now, 111 (54%) set no upper age limit and 74 (36%) stop at 75 or younger; 85 take children under 18; 24 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Leukemia by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.

03

Conditions studied

  • Leukemia
  • Acute Leukemia
  • Relapse Leukemia
  • Refractory Leukemia
  • Refractory Acute Leukemia
  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Mixed Phenotype Acute Leukemia

Keywords

  • Leukemia
  • Acute Leukemia
  • Relapse Leukemia
  • Refractory Leukemia
  • Refractory Acute Leukemia
  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Mixed Phenotype Acute Leukemia
  • Memorial Sloan Kettering Cancer Center
  • 25-229
04

Who can participate

The criteria were revised on the registry on Oct 20, 2026. See what changed

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥ 12 years of age at the time of signing the form (ICF).
  • Participant must weigh at least 40 kg
  • Participant is willing and able to adhere to the study visit schedule and other protocol requirements.
  • Participant has acute leukemia defined acute myeloid leukemia, acute lymphoblastic leukemia, or mixed phenotype acute leukemia after as failure of at least 1 (can be either primary refractory disease or progression during or after treatment)
  • Participant has confirmed acute leukemia with detectable NPM1c, KMT2A translocation, or NUP98 translocation.

    1. At MSK, NPM1 testing utilizes MSK-REACT, a rapid multi-gene NGS panel used in all new AML diagnoses that is clinically validated by the Laboratory of Diagnostic Molecular Pathology pursuant to the requirements of CLIA'88 and approved by New York State, or MSK-IMPACT, a multi-gene NGS panel, which is authorized by the FDA. At non-MSK sites, NPM1 testing may be performed in local CLIA-certified laboratories using validated clinical assays with capable of detecting NPM1c variants at a frequency of ≥5%. Eligible patients must have an NPM1c (nucleophosmin) exon 12 variant as determined by these assays.
    2. At MSK, KMT2A and NUP98 testing will utilize chromosomal analysis and fluorescence in situ hybridization studies. At non-MSK sites, testing may be performed in local CLIA-certified laboratories using validated clinical assays with performance characteristics sufficient to detect relevant translocations. Eligible patients must have a KMT2A or NUP98 translocation as determined by these assays
    3. The patient's chart will be utilized for screening purposes
  • Regarding prior treatment with a menin inhibitor:

    1. Participants enrolled in Phase 1 have no requirements regarding prior treatment with a menin inhibitor
    2. Participants enrolled in Phase 2, cohort 1, are required to be menin inhibitor naïve (no previous treatment with a menin inhibitor)
    3. Participants enrolled in Phase 2, cohort 2, are required to be menin inhibitor exposed (previous treatment received a menin inhibitor)
  • Regarding prior alloSCT, at 60 days must have elapsed from day of transplant and at least 4 weeks must have elapsed from most recent donor lymphocyte infusion.
  • Participant has an (ECOG) performance status score 0-2 (if aged ≥18 years); Performance Scale of ≥50 (if aged ≥16 years and \<18 years); Lansky Performance Score of ≥50 (if aged \<16 years).
  • Participant must have a WBC count \<25,000/μL at the time of initiation of study drug (leukapheresis may be performed and/or hydroxyurea may be administered to decrease the WBC count to \<25,000/μL).
  • Participant has adequate organ function defined as:

    1. Serum /serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 3 x , unless considered due to leukemic organ involvement.
    2. Serum total \< 1.5 x ULN. Higher levels are acceptable if these can be attributed to ineffective erythropoiesis, leukemia organ involvement or Gilbert's syndrome.
    3. Serum creatinine \< 2 x ULN or estimated 60 mL/min or greater based on local institutional practice for age-appropriate determination (e.g, Schwartz formula for pediatric patients or formula for adults).
    4. Adequate cardiac function defined as of ≥ 50% by echocardiogram or multigated acquisition scan.

Exclusion criteria

Exclusion Criteria:

  • Participants with acute promyelocytic leukemia
  • Participants with isolated myeloid sarcoma
  • Participants who have previously received mezigdomide.
  • Participants with immediate life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, disseminated intravascular coagulation, or uncontrolled tumor lysis syndrome.
  • Participant has presence of any other condition that may increase the risk associated with study participation, and in the opinion of the treating investigator, would make the patient inappropriate for entry into the study.
  • Participants with concurrent other that will confound interpretation of study endpoints.
  • Participants who have received other anti-leukemia therapy within 5 half-lives of the agent or 14 days, whichever is sooner, prior to study treatment and if toxicity related to said agent has not resolved; exceptions of acceptable concomitant therapies are listed below

    1. Prior or ongoing revumenib therapy does not require a prior to study treatment
    2. Concomitant cytoreductive therapy in the form of hydroxyurea, , or cytarabine is permitted.
    3. Concomitant therapy in the form of intrathecal chemotherapy for CNS treatment, is permitted.
    4. Radiation therapy is not permitted except for localized palliative radiation to focal lesions after discussion with the Medical Monitor for patients who have progressed but remain on the study due to perceived clinical benefit per Investigator assessment
  • Participants with active (GVHD) of grade 2 or higher requiring systemic treatment. Skin GVHD solely managed with topical corticosteroids would not be exclusionary.
  • Participant has significant active cardiac disease within 6 months prior to start of study treatment, including (NYHA) class III or IV congestive heart failure; acute coronary syndrome (ACS); and/or stroke.
  • Participant has (i.e., Fridericia's correction [QTcF]) ≥ 450 ms (mean of triplicate ) or other factors that increase the risk of QT prolongation or ventricular arrhythmic events (e.g., family history of long QT interval syndrome). Patients with a QTcF over 450 ms due to a bundle branch block or a pacemaker may participate in the study with approval of the study principal investigator.
  • Participant has active viral infection with (HIV), or active infection with virus (HBV) or virus (HCV)
  • Participant is known to have dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.
  • Participant has active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment).
  • Participant with active use of strong inhibitors or strong CYP3A4 inducers. Details reviewed in Appendix B.
  • Participant with use of proton pump inhibitors less than 2 weeks prior to initiating treatment
  • Female participant who is pregnant or lactating. Male or female participants not willing to comply with requirements, which include 4 months of contraception after last dose of revumenib for males and 6 months for females. Additional contraception details reviewed in Appendix D.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Phase 1A

    The first cohort of 3 patients will be treated at dose level 1A

    Drug: Revumenib · Drug: Mezigdomide

  • Experimental
    Phase 1B

    The next cohort of patients will not be treated until toxicity has been evaluated in the current cohort of patients.

    Drug: Revumenib · Drug: Mezigdomide

  • Experimental
    Phase 1C

    The next cohort of patients will not be treated until toxicity has been evaluated in the current cohort of patients.

    Drug: Revumenib · Drug: Mezigdomide

  • Experimental
    Phase 2: Menin Inhibitor Naive Cohort

    In the menin-inhibitor naïve cohort, there will be up to 24 patients, including up to 6 patients from the phase I portion of the study

    Drug: Revumenib · Drug: Mezigdomide

  • Experimental
    Phase 2: Menin Inhibitor Exposed Cohort

    In the menin-inhibitor exposed cohort, there will be up to 16 patients, including up to 6 patients from the phase I portion of the study

    Drug: Revumenib · Drug: Mezigdomide

Interventions

  • Revumenib is a novel menin inhibitor

    Also known as: SNDX-5613

  • Mezigdomide (CC-92480) is an investigational CELMoD.

    Also known as: CC-92480

06

What researchers measure

Primary outcomes

  1. Phase I: Maximum Tolerated Dose

    Maximum Tolerated Dose/MTD is defined as the highest dose level in which 6 participantshave been treated with at most 1 instance of dose limiting toxicities/DLT.

    Time frame: 1 year

07

Study locations

7 of 10 sites recruiting
  • City of Hope Cancer Center (Data collection only)
    Duarte, California 91010, United States
    Not yet recruiting
    • Ibrahim Aldoss, MD · Contact877-814-1610
  • Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Kuo-Kai Chin, MD · Contact646-608-4415
  • Memorial Sloan Kettering Monmouth (All Protocol Activities)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Kuo-Kai Chin, MD · Contact646-608-4415
  • Memorial Sloan Kettering Bergen (All Protocol Activities)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Kuo-Kai Chin, MD · Contact646-608-4415
  • Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities)
    Commack, New York 11725, United States
    Recruiting
    • Kuo-Kai Chin, MD · Contact646-608-4415
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)
    Harrison, New York 10604, United States
    Recruiting
    • Kuo-Kai Chin, MD · Contact646-608-4415
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    Recruiting
    • Kuo-Kai Chin, MD · Contact646-608-4415
  • Memorial Sloan Kettering Nassau (All Protocol Activities)
    Rockville Centre, New York 11553, United States
    Recruiting
    • Kuo-Kai Chin, MD · Contact646-608-4415
  • University of North Carolina (Data Collection Only)
    Chapel Hill, North Carolina 27514, United States
    Not yet recruiting
    • Joshua Zeidner, MD · Contact984-974-8763
  • MD Anderson Cancer Center (Data Collection Only)
    Houston, Texas 77030, United States
    Not yet recruiting
    • Ghayas Issa, MD · Contact713-792-6161
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jan 2029, 36 months after the start.

Of 45 non-industry phase 1/2 interventional studies under Leukemia, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 58 and three quarters within 95. This study's planned 36 months is below that.

Counting every sponsor, half of 77 studies reached it within 79 months; a quarter within 55 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2026
First posted
Jan 21, 2026
StartActual
Jan 16, 2026
Primary completionEst.
Jan 16, 2029
CompletionEst.
Jan 16, 2029
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited, 1 added
What changed in the criteria
Inclusion criteria
  • EditedRegarding prior alloSCT, at 60 days must have elapsed from day of transplant and at least 4 weeks must have elapsed from first dose ofmost recent donor lymphocyte infusion.
Exclusion criteria
  • AddedPrior or ongoing revumenib therapy does not require a washout period prior to study treatment
  • EditedParticipant with active use of strong or moderate CYP3A4 inhibitors or strong CYP3A4 inducers. Details reviewed in Appendix B.
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • EditedRegarding prior alloSCT, at 60 days must have elapsed from day of transplant and at least 4 weeks must have elapsed from first dose ofmost recent donor lymphocyte infusion.
    Exclusion criteria
    • AddedPrior or ongoing revumenib therapy does not require a washout period prior to study treatment
    • EditedParticipant with active use of strong or moderate CYP3A4 inhibitors or strong CYP3A4 inducers. Details reviewed in Appendix B.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07356154
Responsible party
Sponsor
First posted
Jan 21, 2026
Start date
Jan 16, 2026
Primary completion
Jan 16, 2029 (estimated)
Completion
Jan 16, 2029 (estimated)
Last update
Oct 20, 2026

Study contacts

Kuo-Kai Chin, MD
Contact
Chin3@mskcc.org
646-608-4415
Eytan Stein, MD
Contact
SteinE@mskcc.org
646-608-3749
Kuo-Kai Chin, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Revumenib · Mezigdomide

Start the discussion